This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) (SECuRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04868604
Recruitment Status : Recruiting
First Posted : May 3, 2021
Last Update Posted : March 27, 2024
Information provided by (Responsible Party):
Clarity Pharmaceuticals Ltd

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 2026
Estimated Study Completion Date : September 2026